Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afrezza vs Insulin Lispro Dose Response in T1DM
NCT02470637Phase 1Completed
- Sponsor
- MannKind
- Start
- Jun 2015
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TI-Inhalation Powder B in type 1 diabetes mellitus (T1D), sponsored by MannKind. Primary endpoint: Area under the glucose infusion rate curve at 24 hours. Started Jun 2015; status: completed.
02
Drugs
TI-Inhalation Powder B
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02470637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470637.